Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer

Cancer Immunology Immunotherapy, Journal Year: 2025, Volume and Issue: 74(4)

Published: Feb. 25, 2025

The benefits of continuing immunotherapy beyond disease progression in advanced non-small cell lung cancer (NSCLC) and small (SCLC) remain uncertain, along with the specific patient subgroups that may gain most from this approach. This retrospective study aims to evaluate efficacy approach identify target populations likely benefit. We collected data patients NSCLC SCLC who experienced following initial immune checkpoint inhibitor (ICI) treatment January 2020 December 2023. Patients were categorized based on second-line treatment: those receiving (IBP) non-immunotherapy (NIBP). Survival outcomes safety compared between these two groups. A total 150 included, 111 (IBP: n = 78, NIBP: 33) 39 31, 8). Significant differences median progression-free survival (PFS) overall (OS) found driver gene-negative (mPFS: 4.7 vs 1.3 months, HR 0.29, P < 0.01; mOS: 11.03 2.63 0.13, 0.001) 3.9 2.1 0.38, 0.02; 9.28 2.27 0.23, 0.01). Additionally, among patients, achieving a partial response (PR) or stable (SD) during was associated improved effectiveness continued progression. Continued as benefit have progressed after immunotherapy.

Language: Английский

Efficacy of immune checkpoint inhibitors rechallenge and metronomic cyclophosphamide with or without bevacizumab in metastatic nonsmall cell lung cancer

Anti-Cancer Drugs, Journal Year: 2025, Volume and Issue: unknown

Published: April 30, 2025

The present study aims to evaluate the efficacy of immune checkpoint inhibitor (ICI) rechallenge in combination with metronomic cyclophosphamide, or without bevacizumab, patients metastatic nonsmall cell lung cancer (NSCLC) and investigate clinical characteristics associated response therapy. included 43 NSCLC who responded ICIs for ≥4 months subsequently experienced disease progression. then underwent ICI along either oral cyclophosphamide daily alone (n = 24) bevacizumab 19). Combining resulted an objective rate (ORR) 16.7%, control (DCR) 75.0%, median progression-free survival (PFS) 5.8 months, overall (OS) 15.4 months. Oral cohort achieved ORR 26.3%, a DCR 78.9%, PFS 6.8 OS 17.6 No treatment-related adverse events discontinuation therapy cohort. Multivariate analysis demonstrated that absence initial (OS: P 0.016), poor Eastern Cooperative Oncology Group Performance Status (ECOG PS) (PFS: 0.017, OS: 0.032), neutrophil-to-lymphocyte ratio (NLR) ≥ 3.8 0.004, 0.007) were negative predictors showed promising antitumor activity well-tolerated safety profile ICI-pretreated NSCLC. Furthermore, ECOG PS 0-1, response, NLR ≤ predictive

Language: Английский